On March 15, 2021, Texas Health and Human Services Commission (HHSC) will change the Preferred Drug List (PDL) prior authorization criteria for the “Macrolides (oral)” class. The new exception will allow FDA-indicated shorter treatment duration with certain preferred products (such as azithromycin) before approval of a non-preferred option.
Currently, the PDL Criteria Guide asks:
- Has the client failed a 7-day treatment trial with at least one preferred agent in the last 180 days?
The revised version will change to:
- Has the client failed a 7-day treatment trial with at least one preferred agent in the last 180 days? (An exception may apply when a preferred drug requires less than a 7-day treatment trial.)
HHSC will publish an update to the PDL Criteria Guide with this change on March 15, 2021.
Email questions about this change to email@example.com.